p53 mutations in human bladder cancer
โ Scribed by Wolfgang C. Kusser; Xili Miao; Barry W. Glickman; Joan M. Friedland; Nathaniel Rothman; George P. Hemstreet; John Mellot; David C. Swan; Paul A. Schulte; Richard B. Hayes
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 484 KB
- Volume
- 24
- Category
- Article
- ISSN
- 0893-6692
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
We investigated if the presence of single nucleotide polymorphisms (SNPs) in the XRCC1, XRCC3, and XPD genes were associated with the type and frequency of p53 mutations in bladder cancer. Using a hospital-based case-control study we have previously reported risks for the XRCC1 codon 194, XRCC1 codo
The p53 gene (TP53) is mutated in numerous human cancers. We have used it as a molecular target to characterize the induction of mutations in human skin cancers. About 50% of all skin cancers in normal individuals exhibit p53 mutations. This frequency rises to 90% in skin cancers of patients with th
The relationship between integration with human papillomavirus (HPV) and p53 gene mutations in tissues of prostate cancer was examined. Tissue samples analyzed were obtained by total prostatectomy (29 stage B cancer cases) and from autopsy (22 endocrine therapy-resistant metastatic disease cases). H
## Abstract Although carcinoma of the uterine endometrium is the most frequently diagnosed malignancy of the female reproductive tract, the molecular genetic features of this tumor have yet to be described in significant detail. Since mutations of the __p53__ tumor suppressor gene are the single mo
Previous studies have shown that nuclear p53 over-expression is an indicator of p53 mutations whereas cytoplasmic p53 accumulation is related to wild-type p53 in several kinds of tumors. Cytoplasmic p53 accumulation has been demonstrated to be an independent prognostic factor in colorectal adenocarc